A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.

@article{Kipps2015AP2,
  title={A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.},
  author={Thomas J. Kipps and Herbert A Eradat and Sebastian Grosicki and John Vincent Catalano and Walter Cosolo and Iryna S Dyagil and Sreeni Yalamanchili and Akiko Chai and Srikumar Sahasranaman and Elizabeth A. Punnoose and Deborah Hurst and Halyna Pylypenko},
  journal={Leukemia & lymphoma},
  year={2015},
  volume={56 10},
  pages={2826-33}
}
We evaluated the safety and biologic activity of the BH3 mimetic protein, navitoclax, combined with rituximab, in comparison to rituximab alone. One hundred and eighteen patients with chronic lymphocytic leukemia (CLL) were randomized to receive eight weekly doses of rituximab (arm A), eight weekly doses of rituximab plus daily navitoclax for 12 weeks (arm B) or eight weekly doses of rituximab plus daily navitoclax until disease progression or unacceptable toxicity (arm C). Investigator… CONTINUE READING

From This Paper

Topics from this paper.
34 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

Similar Papers

Loading similar papers…